Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/19/2025

Chlamydia Treatment Guidelines

Abstinence and Treatment

  • Patients treated for chlamydia should abstain from sexual intercourse for 7 days after single-dose therapy or until completion of a 7-day regimen, and should continue to abstain until all sex partners have completed treatment, as recommended by the Centers for Disease Control and Prevention (CDC) 1, 2, 3
  • Sex partners from the previous 60 days should be evaluated, tested, and treated, according to the CDC guidelines 1, 2, 3
  • Timely treatment of all partners is essential to prevent reinfection of the index patient, as emphasized by the CDC 1, 2, 3

Testing and Follow-up

  • Test of cure is generally not needed for patients treated with azithromycin or doxycycline unless symptoms persist, reinfection is suspected, the patient was treated with erythromycin, or the patient is pregnant, as stated in the CDC guidelines 1, 2, 3
  • The following patients should receive a test of cure 3 weeks after treatment:
  • Testing too early (<3 weeks) can lead to false-negative results due to small numbers of organisms and false-positive results due to detection of dead organisms 1, 2
  • All patients should be rescreened approximately 3 months after treatment due to the high risk of reinfection, as recommended by the CDC 1, 2, 3
  • Women should be rescreened whenever they next present for care within 3-12 months after treatment 2
  • Reinfection carries an elevated risk of complications (such as pelvic inflammatory disease) compared to initial infection 1, 2

Patient Education and Prevention

  • Patients should be advised to abstain from sexual intercourse until treatment is complete and all sex partners are treated 1, 2, 3
  • The importance of rescreening at 3 months, regardless of partner treatment status, should be discussed with patients 2
  • Ensuring all sexual partners have been evaluated and treated is crucial to prevent reinfection 1, 2
  • Patients should be informed about the high prevalence of reinfection and the elevated risk of complications in previously treated patients 1, 2